Navigation Links
Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook
Date:4/17/2008

ontrol of capillary, venous, and

arteriolar bleeding by pressure, ligature and conventional procedures

is ineffective or impractical.

-- The launch of the company's V-Link Luer-activated device (LAD) with

VitalShield protective coating, the first needleless IV connector

containing an antimicrobial coating. The protective coating has been

shown to kill on average 99.9 percent of specific common pathogens

(infection-causing microorganisms) within the device that are known to

cause catheter-related blood stream infections, including the highly

treatment-resistant bacteria called methicillin-resistant

Staphylococcus aureus, or MRSA.

-- The announcement of preliminary results of a Phase I/II clinical trial,

in which subcutaneous infusion (under the skin) of GAMMAGARD LIQUID

[Immune Globulin Intravenous (Human)] (IGIV) with Enhanze(TM)

Technology enabled administration of a full monthly dose via a single

site to patients with primary immunodeficiency (PID).

Second Quarter and Full-Year 2008 Outlook

Baxter also announced today that it is raising its earnings outlook for full-year 2008. The company continues to expect sales growth, excluding the impact of foreign exchange, of 5 to 6 percent. Excluding Transfusion Therapies from both 2007 and 2008 and excluding foreign exchange, the company expects sales growth of approximately 6 to 7 percent. Baxter now expects to achieve earnings per diluted share of $3.18 to $3.24, before any special items, and cash flow from operations of approximately $2.6 billion. Previously, the company had provided earnings guidance of $3.10 to $3.18 per diluted share, excluding special items, and expected to generate cash flow from operations of more than $2.5 billion.

For the second quarter of 2008, Baxter expects sales growth of 4 to 5 percent, excluding the impact of foreign exchange, and earnings
'/>"/>

SOURCE Baxter International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
2. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
3. Baxter Named to Dow Jones Sustainability Index for Ninth Consecutive Year
4. Baxter and Novation Sign Multi-Year Contract Extension Valued at Over $200 Million for Medication Delivery Products
5. Baxter Adds Recombinant Protein to Specialty Therapeutics Portfolio
6. Baxter Kidney Patient Education Program Celebrates Tenth Anniversary
7. Baxter Receives 510(k) Clearance From FDA For V-Link With VitalShield, New Antimicrobial Intravascular Technology
8. Baxter Announces FDA Approval of GELFOAM(R) Plus Hemostasis Kit
9. Baxter International Fourth Quarter 2007 Financial Results Conference Call
10. Baxter Issues Urgent Nationwide Voluntary Recall of Heparin 1,000 Units/mL 10 and 30mL Multi-Dose Vials
11. Baxters Costa Rica Facility Recognized With Shingo Prize for Excellence in Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD) ... commercializes proprietary technologies and products for advanced microarray diagnostics, ... for trading in the United States ... to commence on September 17, 2014 on the OTCQX ... trade on the TSX Venture Exchange under its existing ...
(Date:9/17/2014)... MARLBOROUGH, Mass. , Sept. 17, 2014 /PRNewswire/ ... ), a biotechnology company focused on discovering, developing ... needs using RNA-targeted technologies, today announced that it has ... Patent and Trademark Office on its unique delivery ... ® ) to phagocytic cells for the treatment ...
(Date:9/17/2014)... September 17, 2014 Beckman Coulter ... science and healthcare, has renewed its agreement with ... part of the agreement, Personify will continue to streamline ... emphasis on recruitment analytics, including time-to-fill, time-to-source and a ... our agreement with Personify was based on the success ...
(Date:9/17/2014)... 17, 2014 First ... from a truly novel class of anti-infective ... Biopharma, a biopharmaceutical company developing a truly ... it has secured £4.0m ($6.4m) to advance ... against a range of Gram-positive infections including  ...
Breaking Biology Technology:SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 2RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 4Beckman Coulter Signs 3-year RPO Contract with Personify 2Beckman Coulter Signs 3-year RPO Contract with Personify 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7
...  Rhythm announced today that Lex Van der Ploeg, PhD, ... Van der Ploeg brings to Rhythm more than 25 ... and other therapeutic areas. "Lex has considerable ... pathways we are targeting with our ghrelin and melanocortin ...
... for Nanotechnology (LCN) have discovered electronic stripes, called ,charge ... that make up a graphitic superconductor. This is the ... and the finding is likely to have profound implications ... scientists believe will play a key role in the ...
... /PRNewswire-iReach/ --  Quantum Leap Innovations announced today the ... Directors.  Michael Cusumano is the Sloan Management Review Distinguished ... Sloan School of Management, with a joint appointment in ... STAYING POWER , covers six enduring principles for ...
Cached Biology Technology:Rhythm Names Lex Van der Ploeg Chief Scientific Officer 2Graphene earns its stripes 2Michael Cusumano, MIT's Sloan Distinguished Professor of Management, Joins Quantum Leap Innovations Board of Directors 2Michael Cusumano, MIT's Sloan Distinguished Professor of Management, Joins Quantum Leap Innovations Board of Directors 3Michael Cusumano, MIT's Sloan Distinguished Professor of Management, Joins Quantum Leap Innovations Board of Directors 4
(Date:9/16/2014)... to Spain culminating the around the world of the ... how the global ocean works and what is its ... atmosphere is not limited to coastal areas, but also ... and it is already affecting the ocean ecosystem. ,This ... Residence for Researchers in Barcelona, in a congress that ...
(Date:9/16/2014)... 16, 2014 Schizophrenia is associated with increased rates ... of research suggests that the relationship between schizophrenia and ... to use nicotine to self-medicate symptoms and cognitive impairment ... in the current issue of Biological Psychiatry , ... the level of nicotine receptors in the brain was ...
(Date:9/16/2014)... choices such as buying clothing not made in a ... bringing their own bags when they go shopping? According ... Consumer Research , ethical consumption is motivated by a ... practices into action. , "Advocates of ethical consumerism suggest ... of the products they choose, but unfortunately only a ...
Breaking Biology News(10 mins):The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 2The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 3Smoking and schizophrenia linked by alterations in brain nicotine signals 2Why are consumers willing to spend more money on ethical products? 2
... Research Hospital investigators have identified a novel structure in cells ... for eliminating damaged cells and also offers new therapeutic potential. ... work as cells ramp up production of p53 protein following ... how cells respond to the stress that damages DNA. The ...
... is available in Spanish . , A ... cooperators provides new details about how fertilizing soils with ... other cleaning suppliesinto the environment. Farmers add "Class ... their fields as a fertilizer. These biosolids meet federal ...
... Friday, Sept. 9, 2010 -- Keynote speakers have ... set for Dec. 5-8 at the Hilton in the ... conference theme is "Where Discovery Meets Innovation." The ... America conference will cover a wide range of topics ...
Cached Biology News:New insights provide promise for development of tools to protect damaged tissues 2New insights provide promise for development of tools to protect damaged tissues 3Tracking triclosan's field footprint 2
Request Info...
Imject Freund's Complete Adjuvant (FCA)...
... cytoplasmic granules, is a key step ... (e.g. basophils, neutrophils, eosinophils, and mast ... secretory granules contain many proinflammatory mediators ... proteases (Hallgren, 2001). Tryptase, a tetrameric ...
... Safe DNA gel stain was developed specifically for ... bromide for staining DNA in agarose or acrylamide ... mutagenic than ethidium bromide but SYBR Safe stain's ... bromide. SYBR Safe stain comes as a premixed ...
Biology Products: